



Structured Administration and Supply Arrangement (SASA) – Issued for a Health Organisation

TITLE: Japanese Encephalitis Vaccine (Live Attenuated Vaccines); Imojev® and JEspect® / Ixiaro® for administration in all public health units, nursing posts, community health clinics, remote area clinics within WACHS.

1. Authority:

Issued by the Chief Executive Officer (CEO) of the WA Country Health Service (WACHS) under Part 6 of the Medicines and Poisons Regulations 2016.

2. Scope and Criteria:

This SASA authorises the health professionals and actions specified in the table below.

Practitioners:	Enrolled Nurses (EN) when working under the indirect supervision of a Registered Nurse (RN) eligible to administer JE vaccines under the Government of Western Australia Department of Health SASA 030/2-2023		
Practice setting and/or service:	In all public health units, nursing posts, community health clinics, remote area clinics within WACHS.		
Approved activity:	Immunisation against Japanese Encephalitis (JE) infection in persons eligible through the WA Targeted JE Vaccination Program .		
Approved medicine: <ul style="list-style-type: none">Name, form/routeSchedule	<p>Imojev® is the primary vaccine available for the WA Targeted JE Vaccination Program. JEspect® can be given to those who cannot have Imojev®.</p> <ul style="list-style-type: none">Imojev® – live attenuated vaccine subcutaneous injectionJEspect® – inactivated vaccine intramuscular injectionIxiaro® – inactivated vaccine intramuscular injection (Overseas product approved for supply in Australia under Section 19A of the Therapeutic Goods Act 1989)		
	Medicine Name:	Japanese Encephalitis Vaccine (Live Attenuated Vaccine)	Brand: Imojev®
	Form:	Injection	Strength: 0.5 mL (reconstituted)
	Dose:	People aged ≥ 9 months: 0.5 mL	Quantity: One vial containing



		single injection of the reconstituted vaccine		vaccine powder and one vial containing diluent
	Route:	Subcutaneous Injection		
	Medicine Name:	Japanese Encephalitis Vaccine (Inactivated Vaccine)	Brand:	JEspect® / Ixiaro®
	Form:	Injection	Strength:	0.5 mL
	Dose:	<ul style="list-style-type: none"> Infants and children aged \geq 2 months to $<$ 3 years should receive 2 doses, each of 0.25 mL, 28 days apart # Children aged \geq 3 years and adults should receive 2 doses, each of 0.5 mL, 28 days apart. For persons aged \geq 18 years at risk of immediate exposure, the 2 doses of the vaccine can be given 7 days apart. 	Quantity:	Pre-filled syringe
	Route:	Intramuscular Injection		
Approved indication(s) (acute) or public health program:		Immunisation against Japanese Encephalitis (JE) infection in persons eligible through the WA Targeted JE Vaccination Program		
WACHS endorsed policy document(s) e.g. clinical practice guidelines, procedure, policy		Must be used in accordance with the following WACHS endorsed policy document(s): <ul style="list-style-type: none"> • Australian Immunisation Handbook • ATAGI clinical guidance on Japanese encephalitis virus vaccines • Government of Western Australia Department of Health SASA 030/2-2023 • Nursing and Midwifery Board of Australia. Enrolled Nurse Standards for Practice • WA Country Health Service. Medication Prescribing and Administration Policy 		


3. General Conditions:



The approved activity (administration and/or supply) of the identified medicine under this SASA is subject to the following conditions:

- a. The health practitioner must only administer and/or supply the medicine per the above criteria of working under the indirect supervision of a Registered Nurse (RN) eligible to administer JE vaccines under the [Government of Western Australia Department of Health SASA 030/2-2023](#) and within their clinical scope of practice.
- b. Medicine selection, administration and/or supply and monitoring must be in accordance with WACHS endorsed clinical practice guidelines, procedure or procedure identified in section 2 above.
- c. If related to vaccinations, written or documented verbal consent must be obtained from the person, parent or guardian, before each instance of immunisation.
- d. If related to Schedule 8 medicines, administration and/or supply must be in accordance with Part 11 of the Medicines and Poisons Regulations 2016.
- e. Administration and/or supply must be recorded in the patient's health care record and include the minimum requirements outlined in regulation 143 of the Medicines and Poisons Regulations 2016. Record keeping for administration and/or supply is in accordance with Part 12 of the Medicines and Poisons Regulations 2016. S4 administration documentation must be kept for 2 years and S8 administration documentation must be kept for 5 years.
- f. The medicines are procured by an authorised person or an appropriate Medicines and Poisons Permit holder. Procurement, storage, administration and supply is in accordance with Part 9 of the Medicines and Poisons Regulations 2016.

4. Issued by:

Name:	Jeffrey Moffet
Position:	WACHS Chief Executive Officer
Signature:	
Date:	01/04/2025
Expiry:	31/03/2027
Issue number:	V2.0

Enquiries to: Director Public Health Medicine

WACHSAreaOfficeCommunicableDiseaseControl@health.wa.gov.au

5. References:

- a. [Australian Immunisation Handbook, Australian Government Department of Health and Aged Care](#)
- b. [Australian Immunisation Register.](#)



- c. [Department of Health and Aged Care Therapeutics Goods Administration. IXIARO Japanese encephalitis vaccine \(inactivated, adsorbed\) suspension for injection pre-filled syringe](#)
- d. [Government of Western Australia, Department of Health. Immunisation clinical competency assessment: A guide for immunisation providers](#)
- e. [Government of Western Australia, Department of Health. Japanese encephalitis](#)
- f. [Government of Western Australia, Department of Health. Structured Administration and Supply Arrangement \(SASA\) - Administration of Japanese Encephalitis \(JE\) Vaccines by Registered Nurses](#)
- g. [National Vaccine Storage Guidelines: Strive For 5, 3rd ed.](#)
- h. [Nursing and Midwifery Board of Australia. Enrolled Nurse Standards for Practice](#)
- i. [WA Medicines and Poisons Regulations 2016](#)
- j. [WA Country Health Service. Medication Prescribing and Administration Policy](#)
- k. [Western Australian Vaccine Safety Surveillance. Western Australian Department of Health, 2016.](#)

Approval for Issuing (can be removed for publication to internet, original to be kept on record)			
WACHS Medicines and Therapeutics Committee			
Minute number:	5.1	Date endorsed:	24/02/2025
WACHS Senior Medical Practitioner			
Name and position:	Dr Helen Van Gessel		
Date approved:	01/04/2025	Signature:	